Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | BRD2 | P25440 | 1/20 | 0.44 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.44 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4997127 | 0.84 | BRD4 (0.52) | MAPTBRD4POLBALDH1A1KDM4E | |
| SCHEMBL4994979 | 0.82 | LMNA (0.46) | MAPTTP53ALDH1A1KDM4ELMNA | |
| SCHEMBL19787912 | 0.79 | MAPT (0.54) | MAPTTP53BRD4POLBALDH1A1 | |
| SCHEMBL11662580 | 0.79 | KDM4E (0.59) | MAPTTP53BRD4POLBALDH1A1 | |
| SCHEMBL13306422 | 0.79 | PDPK1 (0.50) | MAPTTP53ALDH1A1LMNARXFP1 | |
| SCHEMBL13306839 | 0.79 | MAPT (0.49) | MAPTTP53BRD4ALDH1A1KDM4E | |
| SCHEMBL19787910 | 0.78 | LMNA (0.49) | MAPTTP53BRD4ALDH1A1KDM4E | |
| SCHEMBL13306583 | 0.78 | LMNA (0.51) | MAPTTP53BRD4ALDH1A1KDM4E | |
| SCHEMBL4987734 | 0.77 | MAPT (0.44) | MAPTTP53BRD4POLBALDH1A1 | |
| SCHEMBL4993201 | 0.77 | TP53 (0.53) | MAPTTP53BRD4ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | ENCYSIVE PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | C3AR1, C5, C5AR1 | MAPT 4654/4885TP53 3536/4885BRD4 2776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.